Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2005-03-22
2005-03-22
Davis, Zinna Northington (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S569000, C562S426000, C562S427000
Reexamination Certificate
active
06869975
ABSTRACT:
Compounds, compositions and methods that are useful for the treatment of metabolic disorders, inflammatory diseases and cancer are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in lipid metabolism, inflammation and cell proliferation. The subject compounds are linked biaryl compounds.
REFERENCES:
patent: 4443536 (1984-04-01), Lestina
patent: 4466902 (1984-08-01), Kumagae et al.
patent: 5847008 (1998-12-01), Doebber et al.
patent: 5859051 (1999-01-01), Adams et al.
patent: 6090839 (2000-07-01), Adams et al.
patent: 6156801 (2000-12-01), Ota et al.
patent: 6300364 (2001-10-01), Shimokawa et al.
patent: 6525094 (2003-02-01), Zhang et al.
patent: WO 9601317 (1996-01-01), None
patent: WO 9727857 (1997-08-01), None
patent: WO 9728115 (1997-08-01), None
patent: WO 9728137 (1997-08-01), None
patent: WO 9728149 (1997-08-01), None
patent: WO 98 43943 (1998-10-01), None
patent: WO 9904815 (1999-02-01), None
patent: WO9938845 (1999-08-01), None
patent: WO 0072812 (2000-12-01), None
patent: WO 0078312 (2000-12-01), None
patent: WO0100579 (2001-01-01), None
patent: WO 0100603 (2001-01-01), None
patent: WO 0208188 (2001-01-01), None
patent: WO 0117994 (2001-03-01), None
patent: WO 01016120 (2001-03-01), None
patent: WO 0160807 (2001-08-01), None
patent: WO 0179197 (2001-10-01), None
patent: WO0182916 (2001-11-01), None
patent: WO 0196311 (2001-12-01), None
patent: WO 0196347 (2001-12-01), None
patent: WO0200633 (2002-01-01), None
patent: WO 0214291 (2002-02-01), None
patent: WO 0228433 (2002-04-01), None
patent: WO 0228434 (2002-04-01), None
patent: WO 0228434 (2002-04-01), None
patent: WO 0250048 (2002-06-01), None
patent: WO 02070011 (2002-09-01), None
patent: WO 02076957 (2002-10-01), None
patent: WO 03084916 (2003-10-01), None
Auwerx et al., 1996, “Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR”, Atherosclerosis 124(suppl.):S29-S37.
Berge et al., 1977, “Pharmaceutical salts”, J. Pharmaceut. Sci. 66:1-19.
Bisgaier and Pape, 1998, “High density lipoprotein: are elevated levels desirable and achievable?”, Curr. Pharmaceut. Des. 4:53-70.
Hartwig, 1998, “Carbon-heteroatom bond-forming reductive eliminations of amines, ethers, and sulfides”, Acc. Chem. Res. 31:852-860.
He et al., 1999, “PPARδ is an APC-regulated target of nonsteriodal anti-inflammatory drugs”, Cell 99:335-345.
Johnson et al., 1998, “Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus”, Ann. Pharmacother.32:337-348.
Kelley and Killian, 1998, “Troglitazone”, Curr. Opin. Endocrinol. Diabetes 5:90-96.
Kita et al., 1995, “Novel and direct nucleophilic sulfenylation and thiocyanation of phenol ethers using a hypervalent iodine (III) reagent”, J. Org. Chem. 60:7144-7148.
Lefebvre et al., 1997, “Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates”, Arterioscler. Thromb. Vasc. Biol. 17:1756-1764.
Lehmann et al., 1995, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)”, J. Biol. Chem. 270:12953-12956.
Leutenegger et al., 1997, “Double-masked, placebo-controlled, dose-ranging study of troglitazone 10 to 200 mg once daily in non-insulin-dependent diabetes mellitus”, Curr. Therapeut. Res. 58:403-416.
Oliver et al., 2001, “A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport”, Proc. Natl. Acad. Sci. USA 98:5306-5311.
Palomo et al., 2000, “Phosphazene bases for the preparation of biaryl thioethers from aryl iodides and arenethiols”, Tetrahedron Lett. 41:1283-1286.
Patani and LaVoie, 1996, “Bioisosterism: a rational approach in drug design”, Chem. Rev. 96:3147-3176.
Staels and Auwerx, 1997, “Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones”, Curr. Pharmaceut. Des. 3:1-14.
Abe Hiroyuki
Houze Jonathan
Kawasaki Hisashi
Kayser Frank
Sharma Rajiv
Davis Zinna Northington
Japan Tobacco Inc.
Jones Day
Tularik Inc.
LandOfFree
Linked biaryl compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Linked biaryl compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Linked biaryl compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3423128